Medscape EDUCATION

LOOKING AT ALL THE PIECES OF THE HYPERPHOSPHATEMIA PUZZLE IN DIALYSIS-DEPENDENT CKD

Authors: Matthew Weir, MD; Leah D. Foster-Smith, MSN, APRN, FNP-BC, CNN-NP, FNKF, FANNA, FAANP

Supported by an independent educational grant from Ardelyx.

Target Audience and Goal Statement

This activity is intended for an audience of nephrologists, nurse practitioners/physician assistants, renal dieticians, and nurses in the United States.

The goal of this activity is for learners to be better able to understand the roles of the care team and optimize their approach to phosphate-lowering in people living with hyperphosphatemia in dialysis-dependent chronic kidney disease (CKD).

Learning Objectives

Upon completion of this activity, participants will:

- Have increased knowledge regarding the
  - Differentiating characteristics of conventional phosphate binders and novel phosphate-lowering agents
- Demonstrate greater confidence in their ability to
  - Stay abreast of the latest recommended strategies for managing hyperphosphatemia in CKD

Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.

Faculty

Matthew Weir, MD
Professor and Chief, Division of Nephrology
Department of Medicine
University of Maryland School of Medicine
Baltimore, Maryland

Matthew Weir, MD, has the following relevant financial relationships:
☒ Consultant or advisor for: Alnylam; AstraZeneca; Bayer; Boehringer-Ingelheim; Corcept; CSL Vifor; Idorsia; Mineralys; Novo Nordisk; Vera

Leah D. Foster-Smith, MSN, APRN, FNP-BC, CNN-NP, FNKF, FANNA, FAANP
Director of Advanced Practice Providers
Metrolina Nephrology Associates
Chief Education Officer
Interactive Nephrology
Charlotte, North Carolina

Leah D. Foster-Smith, MSN, APRN, FNP-BC, CNN-NP, FNKF, FANNA, FAANP, has no relevant financial relationships.

Editor

Frederick Stange, DO
Medical Education Director, Medscape Education

Frederick Stange, DO, has no relevant financial relationships.

Peer Reviewer
This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Disclaimer

- The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred.
- The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.
- Medscape Education © 2025 Medscape, LLC